Archive

This year CHEPLAPHARM donates €200,000 for the association Deutsch-Afrikanische Zusammenarbeit e.V. and 4.000€ for the Christmas Campaign of the…

Cheplapharm successfully closes the first project with LEO Pharma

This week CHEPLAPHARM successfully closed the project with LeoPharma, which…

This week Cheplapharm closed another deal of a product bundle which contains six molecules and 12 related brands, focused on the treatment of…

CHEPLAPHARM Arzneimittel GmbH has successfully gained a foothold in the US American institutional bond market.

CHEPLAPHARM Arzneimittel GmbH Announces Pricing of

€575 Million 4.375% Senior Secured Notes due 2028

$500 Million 5.500% Senior Secured Notes due…

Greifswald, 06/22/2020

Almost a year after the topping-out ceremony in March 2019, the extension at the companies headquarters in Greifswald (Ziegelhof) is ready for…

Greifswald, 01/31/2020 – AstraZeneca and CHEPLAPHARM have agreed to transfer the commercial rights for SEROQUEL® and other related brands for the…

CHEPLAPHARM Arzneimittel GmbH, a repeat issuer in the long-term loan market with 980 million euros of institutional term loan (“TLB”) outstanding,…

Cheplapharm has priced €500 million aggregate principal amount of its 3.500% senior secured notes due 2027 (the “Notes”), at an offering price of…

Cheplapharm Arzneimittel GmbH has launched an offering of €400 million aggregate principal amount of senior secured notes due 2027.

AstraZeneca has agreed to sell the global commercial rights - excluding China, Japan, the U.S. and Mexico - to LOSEC® (omeprazole) and associated…

Schwerin/Greifswald (DE), 07/26/2019 – As part of her summer tour through Mecklenburg-Western Pomerania, Minister-President Manuela Schwesig stops by…

London/Greifswald, June 13, 2019 – CHEPLAPHARM Arzneimittel GmbH very successfully closed its third capital markets transaction within just one year.…

Düsseldorf/Greifswald (DE), May 10, 2019 – CHEPLAPHARM Arzneimittel GmbH received the "Axia Best Managed Companies Award" (Axia BMC Award) yesterday.…

Just in time with the arrival of spring, CHEPLAPHARM Arzneimittel GmbH is celebrating the topping-out ceremony for the extension building at its…

"As a perfect addition to an already extremely positive year for CHEPLAPHARM, we were able to start another large project in 2018 with F.…

Following a successful roadshow with Institutional Investors in London, CHEPLAPHARM Arzneimittel GmbH was able to issue another loan (TLB market) in…

CHEPLAPHARM Arzneimittel GmbH continues its successful expansion strategy by purchasing three further global niche products.

CHEPLAPHARM Arzneimittel GmbH continues with its diversification strategy.

CHEPLAPHARM is pleased to announce the acquisition of the commercial rights to ATACAND® (Candesartan Cilexetil) and ATACAND® Plus (fixed-dose…

From August 2018, CHEPLAPHARM expands its Ziegelhof headquarters in the Hanseatic city of Greifswald with a new building on an area of 5,300 square…

CHPLAPHARM Arzneimittel GmbH has successfully completed the refinancing of existing loans and promissory notes.

By acquiring the worldwide rights (except US) for the product VISUDYNE® from the Swiss Novartis Pharma AG, CHEPLAPHARM is now active in the…

In the course of an external credit rating, CHEPLAPHARM is rated B/B1 - and thus stable future outlooks.

CHEPLAPHARM Arzneimittel GmbH is pleased to announce that we have signed definitive agreements with Bristol-Myers Squibb to acquire product SOTALEX®.

Right at the beginning of the year, the fast-growing pharmaceutical company CHEPLAPHARM Arzneimittel GmbH secures the product rights for CYMEVENE®,…

Zurich (CH) / Greifswald (DE), December 15, 2017 – In a formal ceremony at the DKSH headquarters in Zurich, DKSH and CHEPLAPHARM Arzneimittel GmbH…

According to the motto “We are creating a future with perspectives”, mid-sized companies were honored for their sustainable and successful management…

On the occasion of the visit of the German Chancellor Angela Merkel and the Minister of Economics Harry Glawe at CHEPLAPHARM in Greifswald, CEO…

The wholly owned subsidiary of Orexigen Therapeutics, Inc. (OREX), and CHEPLAPHARM Arzneimittel GmbH have executed a distributorship agreement…

The successful company from Greifswald, CHEPLAPHARM Arzneimittel GmbH, continues to grow: 50 new employees have been recruited in the past eight…

With an investment of approximately 340 million euros, CHEPLAPHARM Arzneimittel GmbH breaks all private sector records in Mecklenburg-Western…

Amount of investment in the mid, double-digit million euro range. CHEPLAPHARM creates eight new jobs with this acquisition.

On December 1st CHEPLAPHARM Arzneimittel GmbH moved into a new prestigious office building at Ziegelhof Business Park in the outskirts of the…

The pharmaceutical firm CHEPLAPHARM Arzneimittel GmbH has embarked on the biggest ever investment program in the history of the company.

This…

Additionally, CHEPLAPHARM acquires Glenwood LLC based in New York, USA.

CHEPLAPHARM continues its rapid growth in 2013. The increase in sales…

Products are attained from F. Hoffmann-La Roche and will be exported to more than 90 countries.

Mesekenhagen-based CHEPLAPHARM Arzneimittel GmbH from…

Pharmaceutical product was taken over from AstraZeneca and is distributed in Europe

CHEPLAPHARM, headquartered in Mesekenhagen (Mecklenburg-Western…